| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803838 | ABBVIE | Compositions comprising nebivolol |
Aug, 2026
(2 years from now) | |
| US7838552 | ABBVIE | Compositions comprising nebivolol |
Oct, 2027
(3 years from now) | |
Byvalson is owned by Abbvie.
Byvalson contains Nebivolol Hydrochloride; Valsartan.
Byvalson has a total of 2 drug patents out of which 0 drug patents have expired.
Byvalson was authorised for market use on 03 June, 2016.
Byvalson is available in tablet;oral dosage forms.
Byvalson can be used as method of treating hypertension.
The generics of Byvalson are possible to be released after 04 October, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jun 03, 2019 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
How can I launch a generic of BYVALSON before it's drug patent expiration?
More Information on Dosage
BYVALSON family patents
